Q1 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Ladies and gentlemen, welcome to the SOBI presentation of the Q1 results. I will now hand over to Guido Oelkers, CEO. Please go ahead with your meeting.
()-&
Yes, thank you so much, and welcome, everybody. It's my pleasure to start our presentation and lead you through our Q1 results. If we go to the next slide, our forward-looking statement as per usual. During the call, I will be joined by our CFO Henrik Stenqvist; and our Chief Scientific Officer Milan Zdravkovic.
And maybe without spending too much time on other formalities, let's go straight into the highlights of Q1. We feel that we have actually a fantastic result in Q1. We had 66% revenue growth, 54% at constant currency. So we have achieved close to SEK 3.3 billion of revenues. Organic growth profile, let's say, is pretty much intact with 24%.
We have very strong hemophilia growth. And I would like to point this one out with Elocta growing at 53% at actual currency and 46%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
